Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?

Hias, Julie; Hellemans, Laura; Walgraeve, Karolien; Tournoy, Jos; Vandenbriele, Christophe; Aelst, Lucas Van; Linden, Lorenz Van der

doi:10.1136/ejhpharm-2022-003305

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both the patients with baseline AF and those who developed AF during follow-up had higher cardiovascular mortality, without differences in benefit from treatment with vericiguat [74]. However, in those aged 75 or more vericiguat did not provide any statistically significant benefit although safety was similar to younger patients [75].…”

Section: New Pharmacological Therapies In Hfmentioning

confidence: 99%

Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?

Díez‐Villanueva¹,

Jimenez-Mendez²,

Pérez³

et al. 2023

Cardiology

View full text Add to dashboard Cite

Background Heart failure constitutes one of the leading causes of morbidity and mortality in Western countries, in which it is also the leading cause of hospitalization in elderly patients. The pharmacological therapy of patients with heart failure with reduced ejection fraction (HFrEF) has greatly improved during the last years. Summary The quadruple therapy (sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors) is nowadays the cornerstone of medical treatment since it associates lower risk of heart failure hospitalizations and mortality (also of arrhythmic origin). Cardiac arrhythmias, including sudden cardiac death, are common in patients with HFrEF, entailing worse prognosis. Previous studies addressing the role of blocking the renin-angiotensin-aldosterone system and beta-adrenergic receptors in HFrEF have suggested different beneficial effects on arrhythmia mechanisms. Therefore, the lower mortality associated with the use of the four pillars of HFrEF therapy depends, in part, on lower sudden (mostly arrhythmic) cardiac death. Key Messages In this review, we highlight and assess the role of the four pharmacological groups that constitute the central axis of the medical treatment of patients with HFrEF in clinical prognosis and prevention of arrhythmic events, with special focus on the elderly patient, since evidence supports most benefits provided are irrespective of age, but elderly HF patients receive less frequently guideline recommended medical treatment.

show abstract

Section: New Pharmacological Therapies In Hfmentioning

confidence: 99%